Novartis wins a key OK for Kymriah, but continuing manufacturing woes hobble rollout — rival Gilead CAR-T breaks into Europe
Novartis CAR-T manufacturing woes are continuing to put a crimp in its ability to provide therapy to all potential patients.
The pharma giant reported this morning that the EC has stamped its approval on marketing Kymriah in Europe for B-cell acute lymphoblastic leukemia as well as treatment-resistant adults suffering from diffuse large B-cell lymphoma. But Novartis can only make it available to children with ALL now — adults will have to wait.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters